1,6-二甲基-3,4-二氢异喹啉 | 91753-09-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢异喹啉
• 中文名称: 1,6-二甲基-3,4-二氢异喹啉
• 英文名称: 1,6-Dimethyl-3,4-dihydroisoquinoline
• CAS: 91753-09-2
• 化学式: C₁₁H₁₃N
• 分子量: 159.231
• InChiKey: NOSDHGBETGBBTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  间甲基苯乙腈 在 lithium aluminium tetrahydride 、 polyphosphoric acid (83percent P₂O₅) 作用下， 以 乙醚 、 甲苯 为溶剂， 生成 1,6-二甲基-3,4-二氢异喹啉
  参考文献：
  名称：

  Pitea, Demetrio; Beltrame, Pier Luigi; Ferrazza, Alberto, Gazzetta Chimica Italiana, 1984, vol. 114, # 1/2, p. 35 - 40

  摘要：

  DOI：

文献信息

• KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES
  申请人：Flynn L. Daniel

  公开号：US20080090856A1

  公开（公告）日：2008-04-17

  The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.

  本发明涉及一种在治疗高增殖性疾病和哺乳动物癌症，尤其是人类癌症方面有用的新化合物。该发明还涉及调节激酶活性的方法、药物组合物以及治疗个体的方法，包括或使用这些化合物。优选的化合物是在公式Ia-Iww中列出的活性小分子。
• Enzyme modulators and treatments
  申请人：Flynn L. Daniel

  公开号：US20070078121A1

  公开（公告）日：2007-04-05

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, immunological disorders, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of kinases, including p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein, comprises the step of contacting said kinase protein with the novel compounds.

  提供了新型化合物及其使用方法，用于治疗炎症性疾病、免疫性疾病、过度增生性疾病、癌症以及以高血管化为特征的疾病。在一种优选实施方式中，调节激酶的激活状态，包括p38激酶蛋白、abl激酶蛋白、bcr-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白，包括将该激酶蛋白与新型化合物接触的步骤。
• ENZYME MODULATORS AND TREATMENTS
  申请人：Flynn L. Daniel

  公开号：US20080113967A1

  公开（公告）日：2008-05-15

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, ber-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.

  本发明提供了新的化合物及其使用方法，用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在优选实施例中，调节p38激酶蛋白、abl激酶蛋白、ber-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的激活状态，包括将该激酶蛋白与新的化合物接触的步骤。
• Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases
  申请人：Flynn Daniel L.

  公开号：US20110136760A1

  公开（公告）日：2011-06-09

  The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.

  本发明涉及一种新型化合物，可用于治疗过度增殖性疾病和哺乳动物癌症，特别是人类癌症。本发明还涉及调节激酶活性的方法、制药组合物以及治疗个体的方法，包括或使用该化合物。优选的化合物是在公式Ia-Iww中列出的活性小分子。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES
  申请人：Flynn Daniel L.

  公开号：US20120225057A1

  公开（公告）日：2012-09-06

  Compounds of the present invention, alone and in combination with other active agents, find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to for example malignant melanomas, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

  本发明的化合物，单独或与其他活性剂联合使用，可用于治疗过度增生性疾病、哺乳动物癌症，特别是人类癌症，包括但不限于恶性黑色素瘤、骨髓增生性疾病、慢性粒细胞白血病、急性淋巴细胞白血病、由c-ABL激酶引起的疾病、其致癌形式、异常融合蛋白和多态性蛋白。